VIDEO: More research needed before stopping azacitidine/venetoclax after AML remission
Click Here to Manage Email Alerts
SAN DIEGO — In this video, Catherine Lai, MD, MPH, spoke with Healio about patients with newly diagnosed or relapsed acute myeloid leukemia who stopped treatment with azacitidine/venetoclax after receiving one or more cycles past remission.
The findings about the azacitidine/venetoclax (Venclexta; Genentech, AbbVie) regimen were presented at ASH Annual Meeting and Exposition.
“Ultimately, we still don’t know the correct number of cycles to continue and if we can safely stop treatment for all of our patients,” Lai, an associate professor and physician leader of the Leukemia Clinical Research Unit at University of Pennsylvania’s Perelman Center for Advanced Medicine, said. “I think there may be a select group of patients that benefits from stopping therapy but this needs to be confirmed in a prospective study that’s randomized before making this decision a standard of care.”
Collapse
Healio Interviews
Click Here to Manage Email Alerts